Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EC approves Amgen's biosimilar Avastin

Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said the European Commission approved

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE